ReproCELL Incorporated
4978・Growth Market・Chemicals
Research Support Business
A short- to medium-term revenue base providing research products and services built on iPS cell technology
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment revenue (FY2026 (ending March 2026)) | ¥1,952 million | ¥2,415 million | ↓ |
| Segment profit (FY2026 (ending March 2026)) | ¥97 million | ¥621 million | ↓ |
| Segment assets (end of FY2026 (ending March 2026)) | ¥632 million | ¥646 million | ↓ |
| YoY change in revenue | -19.1% | — | ↓ |
| YoY change in segment profit | -84.5% | — | ↓ |
Business Details
Targeting universities, public research institutions, and pharmaceutical companies as key customers, this segment provides research reagents, human biological samples (cells), contract services such as iPS cell generation and genome editing, and sales of cell measurement instruments. The business operates globally through a four-site structure in Japan, the US, the UK, and India, capturing demand for the shift 'from animal testing to human cell testing' through its 'Human Cell Business Platform.' A key feature is that, since no drug approval is required, new technologies can be monetized within a relatively short period.
Recent Overview
Both revenue and profit declined significantly, though certain initiatives continued in the second half through new product launches
In FY2026 (ending March 2026), the Research Support Business posted revenue of ¥1,952 million (down 19.1% year on year) and segment profit of ¥97 million (down 84.5% year on year), a significant deterioration. The decline in overseas revenue, mainly in the US and UK, is considered the main cause. On the other hand, the company continued to expand its product portfolio, including the launch of sales of the HLA-knockout iPS cell line series 'StemEdit™ Human iPSC non-HLA' in April 2025. Revenue by region was ¥873 million in the US, ¥700 million in the UK, ¥302 million in Japan, and ¥78 million in India.
Key Products
Growth Drivers
- Expansion in demand for research-use human cells and reagents driven by the accelerating shift 'from animal testing to human cell testing'
- Increasing demand for contract services from universities and pharmaceutical companies as the practical application of iPS cell technology progresses
- Leveraging a global sales base through the four-site structure in Japan, the US, Europe, and India, and cross-regional deployment of products and services
- Portfolio expansion through the launch of new products such as the HLA-knockout iPS cell line 'StemEdit™ Human iPSC non-HLA'
- Increasing demand for drug discovery screening platforms as pharmaceutical companies expand adoption of iPS cells in drug discovery applications
Risks
- Risk of stalled budget execution at research institutions in major markets such as the US and UK (the significant decline in overseas revenue this period indicates a deteriorating external environment)
- Risk of obsolescence of existing products and services due to rapid advances in iPS cell technology
- Foreign exchange risk (the majority of revenue depends on overseas sites in the US, UK, and India)
- Risk of intensifying price competition due to entry of similar products and services by competitors
- Risk that continued research and development spending will weigh on profitability (R&D expenses for FY2026 (ending March 2026) were ¥627 million, an increase year on year)
Last updated: June 26, 2026